CAR--话题@MedSci

#CAR-#

459篇内容 | 2268人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781361, encodeId=bdf91e81361a2, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, objectType=article, longId=194692, objectId=93bf194692fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93bf194692fc, replyNumber=0, likeNumber=81, createdTime=2020-11-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93bf194692fc, moduleTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93bf194692fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781352, encodeId=2cc91e8135205, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=NEJM：真正通用无需配型！临床研究显示，CAR-NK治疗完全缓解率达73%，一份捐献者脐带血，能制作100人份CAR-NK, objectType=article, longId=191005, objectId=55b91910052d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55b91910052d, replyNumber=0, likeNumber=72, createdTime=2020-08-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55b91910052d, moduleTitle=NEJM：真正通用无需配型！临床研究显示，CAR-NK治疗完全缓解率达73%，一份捐献者脐带血，能制作100人份CAR-NK, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55b91910052d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781340, encodeId=37211e8134039, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, objectType=article, longId=186372, objectId=76531863e2f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76531863e2f1, replyNumber=0, likeNumber=53, createdTime=2020-11-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76531863e2f1, moduleTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76531863e2f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781342, encodeId=c5121e8134279, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=115, createdTime=2020-03-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781350, encodeId=b9371e81350bc, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Sci Transl Med：以毒攻癌！蝎毒修饰的CAR-T免疫疗法精准对抗胶质母细胞瘤, objectType=article, longId=189486, objectId=ab8018948666, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab8018948666, replyNumber=0, likeNumber=78, createdTime=2020-04-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab8018948666, moduleTitle=Sci Transl Med：以毒攻癌！蝎毒修饰的CAR-T免疫疗法精准对抗胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab8018948666)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781371, encodeId=add31e8137144, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=FDA批准第三款CAR-T细胞治疗产品上市, objectType=article, longId=198097, objectId=5ef419809e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ef419809e19, replyNumber=0, likeNumber=15, createdTime=2021-07-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ef419809e19, moduleTitle=FDA批准第三款CAR-T细胞治疗产品上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ef419809e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781351, encodeId=91da1e81351a7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Science子刊：蝎毒修饰的CAR-T免疫疗法精准对抗胶质母细胞瘤, objectType=article, longId=189610, objectId=3d6f189610d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d6f189610d2, replyNumber=0, likeNumber=59, createdTime=2020-07-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d6f189610d2, moduleTitle=Science子刊：蝎毒修饰的CAR-T免疫疗法精准对抗胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d6f189610d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781337, encodeId=efa21e8133756, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Science：BioNTech针对实体瘤的新型CAR-T疗法在小鼠模型中使肿瘤完全消退, objectType=article, longId=185630, objectId=41c31856306c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c31856306c, replyNumber=0, likeNumber=160, createdTime=2020-11-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c31856306c, moduleTitle=Science：BioNTech针对实体瘤的新型CAR-T疗法在小鼠模型中使肿瘤完全消退, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c31856306c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781359, encodeId=14da1e8135949, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效, objectType=article, longId=194140, objectId=8189194140e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8189194140e6, replyNumber=0, likeNumber=63, createdTime=2021-04-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8189194140e6, moduleTitle=Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8189194140e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781336, encodeId=e40c1e81336aa, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=JACC：CAR-T疗法与不良心血管事件的相关性研究, objectType=article, longId=185057, objectId=0f8f18505e78, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f8f18505e78, replyNumber=0, likeNumber=68, createdTime=2020-06-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f8f18505e78, moduleTitle=JACC：CAR-T疗法与不良心血管事件的相关性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f8f18505e78)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781370, encodeId=97fc1e81370fb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=70, createdTime=2020-07-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781338, encodeId=0e1e1e8133889, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=FDA授予Precigen公司的非病毒多基因CAR-T疗法PRGN-3006孤儿药指定，用于治疗急性髓细胞性白血病, objectType=article, longId=185922, objectId=f2591859220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2591859220a, replyNumber=0, likeNumber=55, createdTime=2020-09-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2591859220a, moduleTitle=FDA授予Precigen公司的非病毒多基因CAR-T疗法PRGN-3006孤儿药指定，用于治疗急性髓细胞性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2591859220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781362, encodeId=5a7f1e81362b5, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=ASCO 前沿 | CAR-T疗法治疗复发/难治性淋巴瘤重大突破汇总, objectType=article, longId=195239, objectId=015b195239ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015b195239ca, replyNumber=0, likeNumber=87, createdTime=2020-08-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015b195239ca, moduleTitle=ASCO 前沿 | CAR-T疗法治疗复发/难治性淋巴瘤重大突破汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015b195239ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781368, encodeId=ed901e813689d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, objectType=article, longId=197391, objectId=8b4a19e3919e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b4a19e3919e, replyNumber=0, likeNumber=80, createdTime=2020-11-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b4a19e3919e, moduleTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4a19e3919e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781358, encodeId=af0d1e81358cc, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, objectType=article, longId=193578, objectId=2e2f1935e8e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e2f1935e8e9, replyNumber=0, likeNumber=149, createdTime=2020-12-31, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e2f1935e8e9, moduleTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e2f1935e8e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781347, encodeId=fef51e813479d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助, objectType=article, longId=187730, objectId=1d2918e73091, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d2918e73091, replyNumber=0, likeNumber=59, createdTime=2021-01-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d2918e73091, moduleTitle=Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d2918e73091)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781364, encodeId=593f1e8136470, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Blood：CD19-CAR-T细胞的内源性TCR表达的去留？, objectType=article, longId=195465, objectId=d8e3195465aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8e3195465aa, replyNumber=0, likeNumber=83, createdTime=2020-12-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8e3195465aa, moduleTitle=Blood：CD19-CAR-T细胞的内源性TCR表达的去留？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8e3195465aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781324, encodeId=33b01e813248e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=英国授权开展全球针对肾脏移植免疫排斥反应的CAR-Treg细胞疗法临床研究, objectType=article, longId=183438, objectId=45b8183438a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45b8183438a1, replyNumber=0, likeNumber=68, createdTime=2020-07-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45b8183438a1, moduleTitle=英国授权开展全球针对肾脏移植免疫排斥反应的CAR-Treg细胞疗法临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45b8183438a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781373, encodeId=09091e813736b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, objectType=article, longId=198425, objectId=61571984251d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61571984251d, replyNumber=0, likeNumber=54, createdTime=2021-03-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61571984251d, moduleTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61571984251d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781334, encodeId=a7c91e8133469, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, objectType=article, longId=184956, objectId=2ccf1849567a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ccf1849567a, replyNumber=0, likeNumber=64, createdTime=2020-11-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ccf1849567a, moduleTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ccf1849567a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致

2020-11-22

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

NEJM：真正通用无需配型！临床研究显示，CAR-NK治疗完全缓解率达73%，一份捐献者脐带血，能制作100人份CAR-NK

2020-08-01

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者

2020-11-24

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-03-27

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Sci Transl Med：以毒攻癌！蝎毒修饰的CAR-T免疫疗法精准对抗胶质母细胞瘤

2020-04-10

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

FDA批准第三款CAR-T细胞治疗产品上市

2021-07-07

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Science子刊：蝎毒修饰的CAR-T免疫疗法精准对抗胶质母细胞瘤

2020-07-21

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Science：BioNTech针对实体瘤的新型CAR-T疗法在小鼠模型中使肿瘤完全消退

2020-11-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效

2021-04-07

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

JACC：CAR-T疗法与不良心血管事件的相关性研究

2020-06-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2020-07-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

FDA授予Precigen公司的非病毒多基因CAR-T疗法PRGN-3006孤儿药指定，用于治疗急性髓细胞性白血病

2020-09-02

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

ASCO 前沿 | CAR-T疗法治疗复发/难治性淋巴瘤重大突破汇总

2020-08-10

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准

2020-11-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请

2020-12-31

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助

2021-01-24

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Blood：CD19-CAR-T细胞的内源性TCR表达的去留？

2020-12-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

英国授权开展全球针对肾脏移植免疫排斥反应的CAR-Treg细胞疗法临床研究

2020-07-13

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA

2021-03-26

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可

2020-11-28

科室
- - 订阅+
  - 更多科室
工具
服务